CHANGES IN HISTAMINE CONTENT FOLLOWING PHARMACOLOGICALLY-INDUCED MAST CELL DEGRANULATION IN THE RAT CONJUNCTIVA

Compound 48/80 was applied into one eye of male Wistar rats and a drop of vehicle into the contralateral eye. Another group of rats received sodium cromoglycate in both eyes every 6 h for a period of 48 h. One eye was challenged with compound 48/80 30 min after the end of treatment with sodium cromoglycate. The eyes were monitored clinically and the histamine content of the conjunctiva was determined fluorometrically. The basal histamine levels in rat conjunctival homogenates were quantified. Pharmacologically-induced mast cell degranulation by a single application of 0.1 g ml(-1)of compound 48/80 resulted in significant decreases of conjunctival histamine levels 1, 12 and 24 h after challenge. Sodium cromoglycate prevented the effect of compound 48/80 when administered into the eye prior to the challenge with the non-immunogenic histamine releaser. Upon termination of the application, the membrane stabilizer was unable to reverse the reduced histamine levels in the conjunctival homogenates.     

Role of endogenous serotonin and histamine in the pathogenesis of gastric mucosal lesions in unanaesthetised rats with a single treatment of compound 48/80, a mast cell degranulator.

In unanaethetised rats with a single injection of compound 48/80, a mast cell degranulator (0.75 mg kg-1, i.p.), gastric lesions occurred with increased serum serotonin and histamine levels and reduced gastric mucosal blood flow at 0.5 h after the injection and developed at 3 h. Pretreatment with either cyproheptadine (a serotonin and histamine antagonist) or methysergide (a serotonin antagonist) prevented the formation of gastric mucosal lesions with attenuation of reduced gastric mucosal blood flow at 0.5 h after compound 48/80 injection, while pretreatment with either amitriptyline (a selective inhibitor of histamine release from mast cells), tripelennamine (a histamine H1-receptor antagonist), famotidine (a histamine H2-receptor antagonist) or cimetidine (a histamine H2-receptor antagonist) had no effect. Pretreatment with either cyproheptadine, methysergide, amitriptyline or tripelennamine prevented the development of gastric mucosal lesions at 3 h after compound 48/80 injection, while pretreatment with either famotidine or cimetidine had no effect. These results indicate that in unanaesthetised rats with a single compound 48/80 treatment, acutely released endogenous serotonin causes gastric mucosal lesions, while released endogenous histamine mainly contributes to the lesion development and that gastric acid plays little role in the pathogenesis of the compound 48/80-induced acute gastric lesions.     

Alterations in histamine levels in the rat induced by compound 48/80

Histamine release in the rat was induced in vivo either by a single dose of compound 48/80 injected i.v. or by four repeated, daily doses of the same compound injected i.p. After i.v. injection the levels of blood histamine were determined and after i.p. injections the changes in both tele-methylhistamine and histamine levels in different tissues were investigated. I.v. injection of 48/80 induced a very rapid and marked increase of blood histamine by 7.4 to 11-fold over the control levels within the first two minutes. After repeated i.p. injections of compound 48/80 most tissues showed higher than normal tele-methylhistamine/histamine ratios. The results suggest that agents known to induce release of histamine from mast cells may exert significant changes in blood and tissue histamine levels and that liberated histamine is thereafter extensively catabolized.     

Interaction of astemizole and other drugs with passive cutaneous anaphylactic and histamine-, serotonin-, and compound 48/80-induced skin reactions in the rat: A Procedure to determine anti-allergic effectiveness

Passive cutaneous anaphylactic (PCA) reactions in rats were induced simultaneously with skin reactions to intradermally injected histamine, serotonin, and compound 48/80. In this test compounds with widely different pharmacological profiles were studied to evaluate the significance of anti-allergic activity. Five cromoglycatelike drugs, injected i.v. 5 min before antigen challenge, were either devoid of activity or significant inhibition of PCA reactions was associated to inhibition of histamine and compound 48/80 reactions. Two histamine H₁-antagonists, astemizole and ketotifen; the serotonin S₂-antagonist ketanserin; and the α-adrenergic blocking agent prazosin were tested over a wide dose range 2 hr after s.c. administration. Prazosin, as a result of systemic hemodynamic effects, significantly inhibited the four reactions (primarily PCA), but complete inhibition was not obtained. Ketanserin primarily inhibited serotonin reactions, and inhibition of other reactions required high doses. Ketotifen was a very potent and apparently competitive inhibitor of histamine reactions, with a significant effect on PCA and compound 48/80 reactions. Astemizole primarily inhibited histamine and PCA reactions; complete inhibition was reached for the four reaction types. In terms of a practical definition of anti-allergic drugs, i.e., compounds capable of fully suppressing the consequences of allergen challenge in the absence of nonspecific systemic effects, astemizole appears to be a prototype.     

Prostaglandin E2 prevents diclofenac-induced enhancement of histamine release and inflammation evoked by in vivo challenge with compound 48/80 in the hamster cheek pouch

Based on observations obtained by the use of intravital microscopy, we report that prostaglandins (PGs) can exert inhibitory effects on mast cell-dependent inflammation. Thus, the PG-synthesis inhibitors diclofenac and indomethacin potentiated extravasation of plasma evoked by challenge with the mast cell secretagogue compound 48/80. Although the plasma leakage induced by compound 48/80 was in large mediated by histamine, neither diclofenac nor indomethacin potentiated the plasma leakage caused by exogenous histamine. These findings indicated that endogenous PGs inhibited the mast cell-dependent reaction at the level of mediator release. This mode of action was confirmed, as diclofenac was found to enhance the in vivo release of histamine that ensued challenge with compound 48/80. Moreover, the enhancement of the response to compound 48/80 observed after diclofenac treatment was prevented by local administration of PGE2 (30 nM). This inhibition included both the histamine release and the plasma leakage. In addition, diclofenac enhanced the leukocyte emigration after compound 48/80 challenge, and PGE2 reversed also this effect, suggesting that endogenous PGs (e.g. PGE2) also inhibited the release of chemotactic mediators.     

Activation of connective tissue-type and mucosal-type mast cells in compound 48/80-induced airway response

The pathology of non-immunological airway contraction is not well understood. To define the activation of different phenotypes of mast cells, a rat non-immunological asthmatic model was prepared. Airway contraction in rats was measured by an unrestrained whole-body plethysmographic system following a 10-min inhalation challenge with a 5% solution of compound 48/80. Histamine, leukotrein C(4) (LTC(4)) and tumor necrosis factor (TNF)-alpha levels in bronchoalveolar lavage fluid, as well as tissue histamine content were quantified. Mast cells and eosinophils were detected by histology. Both the early and late phase of airway responses were induced by inhalation of compound 48/80. Histamine and TNF-alpha levels increased significantly 30 min after challenge, but no increases were detected at either 8 or 24 h after challenge. A high LTC(4) level was detected in 30 min and 8 h after challenge. Tissue histamine content decreased at 30 min after challenge and returned to the unstimulated level by 8 h. Connective tissue mast cells in rat trachea showed a degranulation response. Along with the increase in numbers of mucosal mast cells, rat mast cell protease II at both mRNA and protein levels in the trachea epithelial layer was also increased significantly at 30 min after challenge. We conclude that compound 48/80 inhalation causes both the early and late phase of airway contraction in rats. Mast cell degranulation is responsible for the early phase of airway response, which subsequently triggers the late phase of airway response.     

Protective effect of teprenone against acute gastric mucosal lesions induced by compound 48/80, a mast cell degranulator, in rats

The protective effect of teprenone, an anti-ulcer drug, against acute gastric mucosal lesions was examined in rats with a single intraperitoneal injection of compound 48/80 (0.75 mg/kg). Teprenone (50, 100, or 200 mg/kg) was orally administered 0.5 h before compound 48/80 treatment. Administered teprenone prevented gastric mucosal lesion development found at 3 h after compound 48/80 treatment dose-dependently, although no dose of teprenone affected the decreased gastric mucosal blood flow and increased serum serotonin and histamine concentrations found at 3 h after the treatment. Increases in the activities of myeloperoxdiase (an index of neutrophil infiltration) and xanthine oxidase and the content of thiobarbituric acid reactive substances (an index of lipid peroxidation) and decreases in the contents of hexosamine (a marker of gastric mucus) and adherent mucus occurred in gastric mucosal tissues at 3 h after compound 48/80 treatment. Administered teprenone dose-dependently attenuated all these changes found at 3 h after compound 48/80 treatment. These results indicate that orally administered teprenone protects against compound 48/80-induced acute gastric mucosal lesions in rats possibly through its stimulatory action on gastric mucus synthesis and secretion and its inhibitory action on neutrophil infiltration and enhanced lipid peroxidation in the gastric mucosal tissue.     

Effects of prolonged treatment with compound 48/80 on the gastric mucosa and mast cells in the rat

Effects of prolonged administration of compound 48/80 (48/80) on the gastric mucosa, serotonin and histamine levels in serum, and mast cells of rats were studied. Daily administration of 48/80 (0.75 mg/kg, i.p.) for 2 or 4 days produced widespread gastric lesions. Further administration of the agent for up to 12 days did not aggravate the lesions which had developed in the early period of administration of the drug. There were only a few visible lesions and numerous healed ones. Almost the same phenomenon was observed with the daily administration of serotonin plus histamine (10 mg/kg each, i.p.) for 2 to 12 days. While 48/80 given for 2 or 4 days increased serotonin and histamine levels in serum, it induced no appreciable increase of these amines after 8 or 12 days of treatment. Serotonin and histamine levels in peritoneal mast cells significantly decreased after the treatment with 48/80 over a 4 day period. The decrease in gastric lesions after prolonged treatment with 48/80 is due to both the depletion of serotonin and histamine from mast cells and an increased resistance of the gastric mucosa with healed lesions.     

The effect of compound 48/80 on the carbachol-evoked acid secretion of the isolated mouse stomach

The aim of the present work was to determine in the isolated mouse stomach whether the depletion of mast cell histamine by compound 48/80 influences the acid secretion, evoked by carbachol. Each effect of carbachol was compared to the effect of histamine (10(-6) M), applied after each carbachol application. After carbachol and histamine, compound 48/80 was applied twice or three times successively; the second and the third application were not able to evoke any secretion. After 48/80, the applications of carbachol and histamine were repeated and their effects compared to those before the applications of compound 48/80. Three concentrations of the compound were used: 20, 100 and 500 micrograms/ml. The lowest concentration of the histamine liberator did not significantly change the response to carbachol, The highest one reduced it but the effect of histamine was reduced, too. Compound 48/80 in concentration 100 micrograms/ml significantly augmented the secretory effect of carbachol. The possible explanation for this effect is that histamine, liberated from mast cells, is taken up by some other cells in the tissue from where it is liberated by carbachol stimulation.     

Endogenous glucocorticoids inhibit scratching behavior induced by the administration of compound 48/80 in mice

In this study, we investigated the effects of endogenous glucocorticoids on the compound 48/80 (a condensation product of N-methyl-p-methoxyphenethylamine with formaldehyde)-induced mouse scratching behavior using either RU-486 (mifepristone), a glucocorticoid receptor antagonist, or a surgical resection of the adrenal glands. Subcutaneous injection of compound 48/80 induced not only a corticosterone elevation in the plasma but also an enhanced expression of corticotropin releasing hormone (CRH) mRNA in the paraventricular nucleus, which thus suggests that hypothalamic-pituitary-adrenal axis is activated by the compound 48/80-induced cutaneous reaction. Inhibition of such an endogenous glucocorticoid activity by RU-486 significantly increased the degree of scratching behavior at not only the early-phase (<60 min) but also the late-phase (>60 min) time course after the injection of compound 48/80. Since the elevation of the histamine levels in the plasma in the RU-486-treated mice was no longer found in late-phase scratching behavior, these results thus indicate that histamine is a dominant mediator responsible for early-phase scratching behavior, while different mediators other than histamine may be also involved in the induction of late-phase scratching behavior. Moreover, surgical removal of adrenal glands also significantly increased the compound 48/80-induced scratching behavior without affecting anxiety and locomotor parameters, indicating that endogenous glucocorticoids exert their anti-pururitogenic effects independently of changes in behavioral performance. In conclusion, endogenous glucocorticoid activity was found to suppress the compound 48/80-induced scratching behavior in mice.     

Antipruritic effect of ginsenoside rb1 and compound k in scratching behavior mouse models

The antipruritic and vascular permeability-inhibitory effects of ginsenoside Rb1, a main component of ginseng frequently used as a traditional medicine in Asian countries, and its metabolite compound K by intestinal microflora were investigated in scratching behavior animal models induced by compound 48/80, substance P, and histamine. Ginsenoside Rb1 and compound K orally administered 1 and 6 h before the treatment of compound 48/80 showed antipruritic effect. These ginsenosides administered at a dose of 50 mg/kg 6 h before the treatment of compound 48/80 inhibited scratching behaviors by 51% and 64%, respectively, compared with that of the control. These ginsenosides also inhibited the vascular permeability of skin. Compound K intraperitoneally administered 1 h before the treatment of compound 48/80 potently inhibited the scratching behaviors induced by compound 48/80. However, intraperitoneally administered ginsenoside Rb1 did not inhibit scratching behaviors. Compound K inhibited compound 48/80-, substance P-, and histamine-induced scratching behaviors, with 50% inhibitory doses of 4.2, 5.9, and 3.8 mg/kg, respectively, and vascular permeability, with 50% inhibitory doses of 5.8, 6.8, and 4.1 mg/kg, respectively. These results suggest that ginsenoside Rb1 and its metabolite compound K by intestinal microflora can improve scratching behaviors.     

The effect of concentration on the binding of compound 48/80 to rat mast cells: a fluorescence microscopy study

A fluorescent analog of the chemical histamine liberator, compound 48/80, has been synthesized by the covalent attachment of rhodamine to the 48/80 polymer (R-48/80). The histamine liberating characteristics of this analog were similar to those of the parent compound. The binding characteristics of R-48/80 to rat peritoneal mast cells were then studied using fluorescence microscopy. At concentrations that caused minimal secretory stimulation (less than 1.0 microgram/ml), R-48/80 bound to the mast cell surface in a diffuse manner, with no indication of patching or capping. When the cells were incubated at higher concentrations, where non-cytotoxic histamine secretion was stimulated, the drug bound heavily to the exposed granules, but not to unexposed granules or other cell organelles. At cytotoxic concentrations, R-48/80 caused extensive cell clumping, with the drug bound to masses of cell debris and released granules. Therefore, although R-48/80 binds initially to the cell membrane, its primary binding site at concentrations that induce secretion becomes the mast cell granule. The properties of these granules should thus be considered when studying the binding of compound 48/80 or other cationic drugs to rat peritoneal mast cells.     

The utilization of adenosine triphosphate in rat mast cells during histamine release induced by anaphylactic reaction and compound 48/80

Summary The ATP content of rat peritoneal mast cells has been studied in relation to histamine release induced by compound 48/80 and antigen-antibody (anaphylactic) reaction in vitro. When the ATP content of actively sensitized mast cells was reduced to different levels by oligomycin, a good correlation was obtained between the ATP levels and the amounts of histamine released by the anaphylactic reaction. A similar linear relation has previously been demonstrated between the ATP levels of mast cells and histamine release induced by compound 48/80. The ATP content of mast cells was also studied at different intervals after the exposure of the cells to antigen or compound 48/80. No significant change in the ATP content was observed in untreated mast cells during the short period when histamine release occurs. If, however, the mast cells were preincubated with oligomycin or 2-deoxyglucose to reduce the rate of ATP synthesis while a large part of the histamine release remained unaffected—a decrease in the ATP content could be demonstrated in close time relation to both anaphylactic and compound 48/80-induced histamine release. The observations indicate an increased utilization of ATP in mast cells during the release process.     

Effects of multiple dexamethasone treatments on aggravation of allergic conjunctivitis associated with mast cell hyperplasia

In a Japanese cedar pollen-induced allergic conjunctivitis model in guinea pigs, symptoms were aggravated by repeated pollen challenges. In addition, the number of mast cells in the conjunctiva was increased by multiple challenges. The amount of a mast cell mediator, histamine in ophthalmic lavage fluid was also increased by multiple challenges. In the present study, we evaluated the effects of multiple dexamethasone treatments to assess the relationship between the aggravation of symptoms and mast cell hyperplasia. Sensitized guinea pigs were challenged by dropping a pollen suspension onto their eye surface once a week until the 15th challenge. Dexamethasone (10 mg/kg, p.o.) was administered once 3 h before the 15th challenge or 3 h before every 1st--15th challenge. Mast cells in the conjunctival tissue were detected by toluidine blue staining. Histamine was fluorometrically assayed by high-performance liquid chromatography. Serum Cry j 1-specific IgE titer was measured by an enzyme-linked immunosorbent assay. The results indicated that a single treatment with dexamethasone did not affect the 15th challenge-induced symptoms; however, multiple treatments with the corticosteroid suppressed not only conjunctivitis symptoms after every challenge but also the mast cell hyperplasia and the increase in histamine in the lavage fluid. Conversely, the increase in the IgE titer in the serum was not affected by multiple treatments with dexamethasone. In conclusion, increased numbers of mast cells in the conjunctival tissue may be associated with the aggravation of allergic conjunctivitis symptoms.     

The intracerebroventricularly administered mast cells degranulator compound 48/80 increases the pituitary-adrenocortical activity in rats

The effect of brain mast cells degranulation by compound 48/80 on the pituitary-adrenocortical activity, measured indirectly through corticosterone secretion, and the involvement of a histaminergic mechanism in that stimulation was investigated in conscious rats. All the drugs were given intracerebroventricularly (icv), histamine antagonists 15 min prior to compound 48/80. Compound 48/80 induced a significant dose- and time-related increase in the serum corticosterone levels. That increase, measured 1 h after administration of compound 48/80, was moderately diminished by icv pretreatment of rats with mepyramine and cimetidine, histamine H1- and H2-receptor antagonists. Three hours after administration of compound 48/80 mast cells of the thalamus and the hypothalamus were completely degranulated. At the same time the thalamus and the whole brain histamine levels were substantially higher than in the saline-treated control rats. The above results suggest that histamine liberated from the brain mast cells and central histamine receptors play a moderate role in increasing the pituitary-adrenocortical activity by compound 48/80.     

Plasma histamine and catecholamine levels during hypotension induced by morphine and compound 48/80

Histamine receptors are present in adrenergic terminals, and histamine is reported to inhibit release of the neurotransmitter norepinephrine (NE) at certain neuroeffector junctions. However, a physiological role for histamine in modifying adrenergic neurotransmission has not been established. To examine the interaction of elevated plasma histamine and catecholamine release, two compounds that release histamine, morphine (3 mg/kg), and compound 48/80 (0.5 mg/kg), were administered intravenously (i.v.). Plasma norepinephrine (NE) levels were used to monitor sympathetic nervous system activity, and plasma epinephrine (Epi) levels were used to monitor adrenal activity. Both morphine and compound 48/80 caused an immediate and marked increase in plasma histamine. Simultaneous with this increase, a marked decrease in mean arterial pressure occurred. Plasma NE levels increased in animals administered compound 48/80, but in morphine-treated animals, plasma NE levels did not change from pretreatment values. Plasma Epi levels increased in both groups, but the magnitude and duration of the responses differed. The results indicate that elevated plasma catecholamines can increase in response to histamine-induced hypotension but this effect can be suppressed by the central actions of morphine.     

Increased Utilization of Endogenous ATP in Isolated Rat Mast Cells during Histamine Release Induced by Compound 48/80

Abstract: In order to investigate whether the energy dependence of histamine release induced by compound 48/80 from isolated rat mast cells reflects an increased utilization of ATP during the release process, the ATP content in samples of mast cells was determined 5 sec. before and 25 sec. after the addition of compound 48/80. No change in the ATP content was found when histamine release was induced from cells with an intact energy metabolism. However, when the cells had been preincubated for 1 min. with antimycin A to inhibit oxidative production of ATP, histamine release was accompanied by a greater reduction (P < 0.005) in the ATP content than that observed in the control samples. In contrast, when corresponding experiments were performed with chlorpromazine or n-decylamine as releasing agent, the ATP content was not lower in the samples in which histamine release had been induced than in the controls, regardless of whether antimycin A was present or not. The results indicate that histamine release from rat mast cells induced by compound 48/80, but not by chlorpromazine or n-decylamine, is accompanied by an increased utilization of ATP in the cells.     

Inhibitors of mast cell-mediated shock in the rat: Relationship to histamine and serotonin antagonism

Thirteen compounds of heterogenous chemical structure and pharmacologic profile were studied in vivo in tests that measure antagonism of histamine and/or serotonin in the rat. These tests were the compound 48/80-lethality test, skin reactions to histamine and serotonin, the PCA test, and tryptamine-induced bilateral convulsions and tremors. The compounds were always administered orally with a time interval of 2 hr between dose and challenge, to allow quantitative comparisons between activities in different tests. Compounds that preferentially antagonize histamine in the skin test have the same potency rank in the histamine skin test and in the compound 48/80-lethality test. This indicates not only that H₁-antagonism is sufficient to prevent compound 48/80-induced lethal shock, but also that the basis of the protection is the maintenance of a sufficiently large intravascular fluid volume compatible with normal cardiovascular function. Inhibition of a serotonin-induced increase of capillary permeability may also be sufficient to prevent lethal shock, although the ergoline derivatives were much weaker than expected. For full inhibition of PCA-reactions, doses are required that exhibit effective antagonism of both serotonin and histamine. Antagonism of tryptamine-induced bilateral convulsions and tremors, which is a centrally mediated effect, showed no clear relation to any of the peripheral actions that were investigated.     

Physiological activities of S-(1,2-dicarboxyethyl)glutathione as an intrinsic tripeptide present in liver, heart and lens.

S-(1,2-Dicarboxyethyl)glutathione (DCE-GS, CAS 1115-52-2) found in rat liver, heart and lens in considerable amounts, showed an anti-inflammatory effect, which was evaluated by testing the inhibition of the experimental conjunctival edema of rats. An intravenous injection (3 mg/kg) prior to the carrageenan injection prevented the conjunctive edema formation by up to 30%. This peptide also inhibited the histamine release from rat mast cells induced by the compound 48/80. The peptide was added to the mast cells before addition of the compound 48/80 and an inhibition of the histamine release up to 96% at a 1 mmol/l concentration occurred. Furthermore, it displayed an antianaphylactic effect in rats using antibody against chicken egg albumin. An injection of the peptide (30 mg/kg) prior to the antigen administration inhibited color deposition up to 43%. Analogues or derivatives of DCE-GS were synthesized and tested for those inhibitory activities. However, there was no other peptide having stronger effects than DCE-GS and little structure-activity relationship among them.     

Mast cell amines and the oedema induced by zymosan and carrageenans in rats

Cimetidine and metiamide suppressed the paw swelling induced in rats by low doses of histamine while these H2 antagonists had little effect on the oedema induced by 100 micrograms of histamine and inhibited by mepyramine. When administered 0.5 h before the inflammagens, H2 antagonists reduced the oedema induced by zymosan and iota carrageenan; they had a slight effect on the oedema induced by lambda and kappa carrageenans and no effect on the oedema induced by compound 48/80. When administered 18 h before the inflammagens, cimetidine greatly increased zymosan oedema and slightly increased lambda carrageenan oedema. Mepyramine, methysergide or depletion of the 5-hydroxytryptamine stores in mast cells by pretreatment with reserpine inhibited the oedema induced by compound 48/80 and zymosan but did not affect the oedema induced by lambda and kappa carrageenans. Histamine may play a dual role in inflammatory reactions. Mast cell amines take a part in the development of zymosan oedema though they play a minor role in the oedema induced by the carrageenans.